XT
CRVS icon

XTX Topco’s Corvus Pharmaceuticals CRVS Stock Holding History

XTX Topco’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$502K Buy
+34,305
New +$547K 0.01% 2051
2025
Q2 		– Sell
-14,958
Closed -$47.6K – 2496
2025
Q1 		$47.6K Sell
14,958
-42,255
-74% -$199K ﹤0.01% 2004
2024
Q4 		$306K Buy
57,213
+43,127
+306% +$322K 0.03% 1198
2024
Q3 		$74.4K Buy
+14,086
New +$50.6K 0.01% 1646
2024
Q1 		– Sell
-23,415
Closed -$41.2K – 1915
2023
Q4 		$41.2K Buy
23,415
+4,171
+22% +$6.1K 0.01% 1264
2023
Q3 		$28.1K Buy
+19,244
New +$40.7K ﹤0.01% 1342

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

XTX Topco's CRVS Position: Q1 2026 in Review

XTX Topco opened a new position in Corvus Pharmaceuticals (CRVS) in Q1 2026: 34,305 shares worth $502K. The stake represents 0.01% of the portfolio and ranks #2051 among its holdings. This is a return to the name: XTX Topco previously reported a position in CRVS as recently as Q1 2025.

XTX Topco first reported a position in CRVS in Q3 2023 and has held it in 6 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • XTX Topco held 34,305 shares of Corvus Pharmaceuticals worth $502K as of Q1 2026.
  • Corvus Pharmaceuticals was a new XTX Topco position in Q1 2026.
  • Corvus Pharmaceuticals made up 0.01% of XTX Topco's portfolio in Q1 2026, its #2051 holding.
  • XTX Topco first reported a position in Corvus Pharmaceuticals in Q3 2023 and has held it in 6 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.